Search results for "Trials"

showing 10 items of 966 documents

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer

2004

Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was to describe pain prevalence among patients diagnosed with advanced non-small-cell lung cancer (NSCLC), impact of pain on quality of life (QoL) and adequacy of pain management. Data of 1021 Italian patients enrolled in three randomised trials of chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13. Analgesic consumption during the 3 weeks following QoL assessment was recorded. Adequacy of pain management was evaluated by the Pain Management Index (PMI). Some pain was reported by 74% of patients (42% mild, 24% …

AdultMalecancer painCancer Researchmedicine.medical_specialtyLung NeoplasmsAnalgesicPainBone NeoplasmsSeverity of Illness Indexlaw.inventionClinicalPain Management IndexRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungInternal medicineEpidemiologySeverity of illnessPrevalencemedicineHumansPain ManagementAgedPain MeasurementRandomized Controlled Trials as TopicAged 80 and overbusiness.industryGuidelineanalgesicMiddle AgedClinical triallung cancerItalyOncologyanalgesicsQuality of LifePhysical therapyFemalebusinessCancer painBritish Journal of Cancer
researchProduct

Enhancing the efficacy of integrative improvisational music therapy in the treatment of depression : study protocol for a randomised controlled trial

2019

Abstract Background Depression is among the leading causes of disability worldwide. Not all people with depression respond adequately to standard treatments. An innovative therapy that has shown promising results in controlled trials is music therapy. Based on a previous trial that suggested beneficial effects of integrative improvisational music therapy (IIMT) on short and medium-term depression symptoms as well as anxiety and functioning, this trial aims to determine potential mechanisms of and improvements in its effects by examining specific variations of IIMT. Methods/design A 2 × 2 factorial randomised controlled trial will be carried out at a single centre in Finland involving 68 adu…

AdultMalemasennusTime FactorsAdolescentEmotionsmusiikkiterapiaAnxietyresonanssiclinical improvisationStudy ProtocolYoung AdultIntegrative psychotherapyhengitysHumansahdistusimprovisointiLungFinlandRandomized Controlled Trials as TopicResonance frequency breathinglcsh:R5-920DepressionRespirationClinical improvisationBiofeedback PsychologyMiddle AgedpsykoterapiaAffectTreatment OutcomedepressionAuditory PerceptionkotitehtävätFemaleHomeworkMusic therapylcsh:Medicine (General)resonance frequency breathingintegrative psychotherapy
researchProduct

Efficacy and cost-effectiveness of a blended cognitive behavioral therapy for depression in Spanish primary health care:Study protocol for a randomis…

2018

Background: Data from primary health care in Spain show a high prevalence of the major depressive disorder. Blended treatment (combination of face-to-face and online components) seems to be a very promising tool for the optimization and dissemination of psychological treatments in a cost-effective form. Although there is growing data that confirm the advantages of blended therapies, few studies have analyzed their application in regular clinical practice. The objective of the present paper is to describe the protocol for a clinical study aimed at exploring the clinical and cost-effectiveness of a blended cognitive behavioral therapy (b-CBT) for depression, compared to treatment as usual (TA…

AdultMalemedicine.medical_specialtyAdolescentlcsh:RC435-571Cost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisInternet-based treatmentEquivalence Trials as TopicRandomised non-inferiority trial03 medical and health sciencesStudy ProtocolYoung Adult0302 clinical medicinePatient satisfactionQuality of life (healthcare)SDG 3 - Good Health and Well-beinglcsh:PsychiatrymedicineHumans030212 general & internal medicineYoung adultBlended treatmentDepression (differential diagnoses)Randomized Controlled Trials as TopicPrimary health careCognitive Behavioral TherapyPrimary Health Carebusiness.industryDepressionRepeated measures designProfessional-Patient Relationsmedicine.disease3. Good health030227 psychiatryCognitive behavioral therapyCognitive behavioral therapyPsychiatry and Mental healthTreatment OutcomePatient SatisfactionSpainPhysical therapyQuality of LifeMajor depressive disorder/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalebusiness
researchProduct

Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

2011

To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken.Adverse event data were pooled worldwide from 17 clinical efficacy and safety studies. Adverse events were coded using the Medical Dictionary for Regulatory Activities version 5.0.In the pooled clinical trial data set, 3028 patients received at least one dose of micafungin. The mean age of patients was 41.4 years; with 296 (9.8%) children (16 years) and 387 (12.8%) elderly patients (≥ 65 years). Common underlying conditions were hematopoietic stem cell and other transplantations (26.1%), malignancies (20.8%) and HIV (32.9%). Mean exposure was 18 days for adults and 29 days …

AdultMalemedicine.medical_specialtyAntifungal AgentsTime FactorsAdolescentDatabases FactualNauseaMedDRAEchinocandinsLipopeptidesYoung AdultInternal medicinemedicineHumansPharmacology (medical)ChildAdverse effectAgedAged 80 and overClinical Trials as TopicDose-Response Relationship Drugbusiness.industryAge FactorsMicafunginInfantGeneral MedicineMiddle AgedHypokalemiaSurgeryClinical trialDiarrheaMycosesChild PreschoolMicafunginVomitingFemalemedicine.symptombusinessmedicine.drugExpert Opinion on Drug Safety
researchProduct

LDL size: does it matter?

2004

The atherogenic lipoprotein phenotype is characterised by a moderate increase in plasma triglycerides, a decrease in high density lipoprotein cholesterol and the prevalence of smaller denser low density lipoprotein particles. The prevalence of this partially inheritable phenotype is approximately 30% and is a feature of the metabolic syndrome associated with an increased risk for cardiovascular events. The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III.

AdultMalemedicine.medical_specialtyArteriosclerosisCoronary DiseaseCohort Studieschemistry.chemical_compoundHigh-density lipoproteinSex FactorsRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusPrevalenceAnimalsHumansatherogenic lipoprotein phenotypeProspective Studiescoronary heart diseaseRisk factorsmall dense LDLTriglyceridesAgedHypolipidemic AgentsMetabolic SyndromeClinical Trials as Topicdiabetesbusiness.industryCholesterolSmokingAge FactorsGeneral MedicineCholesterol LDLAtherogenic lipoprotein phenotypeMiddle Agedmedicine.diseasePhenotypeLipoproteins LDLEndocrinologyLogistic ModelsPhenotypechemistryLow-density lipoproteinFemaleMetabolic syndromeInsulin ResistancebusinessSwiss medical weekly
researchProduct

Effectiveness of Dry Needling in the Management of Spasticity in Patients Post Stroke.

2020

Abstract Objective: To determine the effectiveness of the dry needling technique (DNT) in the treatment of spasticity for individuals with stroke. Design: We reviewed the Embase, Pubmed/MEDLINE, Web of Science and Cochrane Central Register of Controlled Trials (CENTRAL) databases. We also performed a manual search of the references that are included in the selected articles. Studies included were: i) randomized clinical trials (RCTs); ii) involving patients with a diagnosis of stroke; and iii) using DNT alone or in a multimodal treatment. Muscular spasticity was the primary outcome of the study. The additional outcomes included were: pressure pain sensitivity, range of motion and perception…

AdultMalemedicine.medical_specialtyBlindingMEDLINElaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansSpasticityStrokeAgedRandomized Controlled Trials as TopicDry needlingbusiness.industryRehabilitationMiddle Agedmedicine.diseaseStrokeTreatment OutcomeSample size determinationMuscle SpasticityDry NeedlingPhysical therapySurgeryFemaleNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessRange of motion030217 neurology & neurosurgeryJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
researchProduct

Dose-response relationships and plasma concentrations of digitalis glycosides in man.

1978

An inter-individual, randomized, double-blind study of digitoxin (Dt) and β-acetyl digoxin (D) was performed in 120 healthy male volunteers. Groups of 10 persons each received orally D 0, 0.1, 0.2, 0.3, 0.4, 0.5 or 0.6 mg and Dt 0.04, 0.08, 0.12, or 0.16 mg daily for 7 days; Loading doses were given for the first three days. Plasma levels were measured with an86Rb-erythrocyte assay 24 h after the last dose. ECG, carotid artery pulse and phonocardiogram were recorded prior to (b) and 24 h after (a) the last dose. QTc, amplitude of T-waves in V2 to V6, electromechanical systole (QS2c) and left ventricular ejection time (LVETc) were measured. The differences between a and b (Δ-values) reflect …

AdultMalemedicine.medical_specialtyDigoxinTime FactorsDigoxinDigitoxinQT intervalElectrocardiographyDigitoxinDouble-Blind MethodInternal medicinemedicineHumansPharmacology (medical)Pharmacologychemistry.chemical_classificationClinical Trials as TopicDose-Response Relationship DrugChemistryPulse (signal processing)GlycosideDigitalis GlycosidesHeartGeneral MedicinePlasma levelsEndocrinologySystolic time intervalsPlasma concentrationmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Investigation into isoprenaline resistance in patients with obstructive lung disease

1974

12 patients with chronic obstructive lung disease have been studied in an investigation regarding the causes of resistance to isoprenaline. The effects of repeated intravenous doses of 10 µg isoprenaline were assessed by cross over comparison before and after infusions of isoprenaline and a placebo; the infusions lasted for 35 to 40 min and the amount of isoprenaline infused was 0.5 µg/min. Total resistance, thoracic gas volume (whole-body plethysmography) and heart rate (ECG) were measured. No decrease in bronchospasmolytic or positive chronotopic effects on single isoprenaline injections could be demonstrated after prolonged infusions of isoprenaline.

AdultMalemedicine.medical_specialtyDrug ResistanceDrug resistancePlaceboPlacebosElectrocardiographyHeart RateIsoprenalineInternal medicineHeart ratemedicineHumansPlethysmographInfusions ParenteralPharmacology (medical)Lung Diseases ObstructiveAgedPlethysmography Whole BodyAsthmaPharmacologyAnalysis of VarianceClinical Trials as Topicbusiness.industryAirway ResistanceIsoproterenolGeneral MedicineMiddle Agedmedicine.diseaseStimulation ChemicalObstructive lung diseaseAirway ObstructionBronchodilatationAnesthesiaInjections IntravenousCardiologyFemalebusinessmedicine.drugEuropean Journal of Clinical Pharmacology
researchProduct

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study.

1986

Forty patients with Graves' ophthalmopathy stages III-V were divided into two groups in a random manner according to their year of birth. Group I received prednisone in decreasing dosage. Group II received prednisone at a comparable dosage and ciclosporin. Steroids were discontinued after 10 weeks in the two groups. In the patients of group II, ciclosporin was continued over 12 months. The therapeutic effect was assessed by an activity score based on subjective and objective symptoms (computerized tomography and sonography of the orbit, Hertel values, clinical findings). All signs of endocrine ophthalmopathy improved significantly in both groups (P less than 0.01 in group I; P less than 0.0…

AdultMalemedicine.medical_specialtyEye DiseasesClinical BiochemistryVisual AcuityCyclosporinsBiochemistryGastroenterologylaw.inventionGraves' ophthalmopathyPharmacotherapyRandomized controlled triallawPrednisoneInternal medicinemedicineHumansProspective StudiesProspective cohort studyClinical Trials as TopicDose-Response Relationship Drugbusiness.industryTherapeutic effectGeneral MedicineMiddle AgedCiclosporinmedicine.diseaseGraves DiseaseClinical trialEndocrinologyPrednisoneDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesEuropean journal of clinical investigation
researchProduct

Combination therapy with amantadine and interferon in naı̈ve patients with chronic hepatitis C: meta-analysis of individual patient data from six cli…

2003

Abstract Background/Aims In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre–treatment interaction fitted as random variables. Results At the end of therapy, virological responses were 38.5% (95% CI 34.1–42.8) after INF and AMA, and 29.5% (95% CI 25.5–33.6) after INF alone (P=0.003). Sustained response occurred in 1…

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepacivirusAntiviral AgentsGastroenterologymeta-analysilaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled triallawInternal medicineparasitic diseasesAmantadinemedicinechronic hepatitis CHumansAgedRandomized Controlled Trials as TopictherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinAmantadineAlanine TransaminaseinterferonHepatitis CHepatitis C ChronicMiddle AgedViral Loadrandomized clinical trialmedicine.diseaseClinical trialTreatment OutcomechemistryImmunologyDrug Therapy CombinationFemaleInterferonsbusinessViral loadmedicine.drugJournal of Hepatology
researchProduct